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ABSTRACT 
 
Vascular smooth muscle cells (VSMC) migration and proliferation may be the main precursors of the chronic 
and maladaptive vascular remodeling in hypertension. The proteolysis of extracellular matrix and the phenotype 
switch of VSMC need to occur in order to allow VSMC migration and the vascular remodeling and hypertrophy. 
The matrix metalloproteinases (MMPs) are well known to degrade many extracellular matrix and non-extracellular 
matrix components to favor VSMC migration and their phenotype switch. Targeting MMPs may reduce VSMC 
migration and the arterial maladaptation caused by hypertension and its cardiovascular events. 
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Introduction 
Hypertension is characterized by a sustained 
elevation of arterial pressure1 which causes mechanical 
stress within the arterial wall and leads to vascular 
remodeling.2 The underlying pathological processes in 
vascular remodeling are associated with migration and 
proliferation of vascular smooth muscle cells (VSMC), 
which are located in the tunica media of arteries.3 
Persistent and severe stretching of the vessel wall 
caused by hypertension may also result in VSMC 
hypertrophy, which preferentially occurs in the large 
conduit arteries, such as aorta.2, 4 Hypertension-
induced hypertrophic remodeling is usually observed 
as increased arterial wall thickness, cross-sectional area 
and media to lumen ratio5, 6 and may be the result of 
extracellular matrix (ECM) proteolysis and the 
phenotype switch of contractile to synthetic VSMC.3 
The matrix metalloproteinases (MMPs), a family of 
zinc-dependent proteases, have been implicated in the 
chronic vascular remodeling of hypertension due to 
their proteolytic effects on ECM and non-ECM 
components, which may contribute to the capacity of 
VSMC to migrate and proliferate.7-9 
 
Role of MMPs in maladaptive vascular 
remodeling in hypertension  
Increased activity of MMPs is generally 
observed in animal models of hypertension and 
contributes to excessive ECM proteolysis, VSMC 
reorganization and hypertrophy.10, 11 Among many 
MMPs, the gelatinases (MMP-2 and MMP-9) and 
MMP-14 were associated with increased arterial media 
and intima thicknesses of hypertensive animals.10, 11 
Our group showed that treating two-kidney one-clip 
(2K-1C) hypertensive rats with doxycycline, an MMP 
inhibitor, inhibited MMP-2-induced chronic 
maladaptive vascular remodeling by reducing the 
deposition of elastin and collagen in aortas and the 
VSMC hyperplasia.10 
 
MMPs contribute to VSMC migration: ECM 
proteolysis and VSMC phenotype switch 
The VSMC are the main constituents of the 
tunica media of the vessels wall and significantly 
contribute to maintain their scaffold and tone. In the 
presence of mechanical force or stress and bioactive 
peptides3, 12 the VSMC may switch from contractile 
(differentiated) to synthetic (dedifferentiated) 
phenotype which migrate, proliferate and produce new 
ECM, thus contributing to hypertension and its 
chronic vascular remodeling. In fact, VSMC exposed 
to cyclic stretch in vitro displayed more elongated 
morphology and a significant proliferation capacity.  
For VSMC migration and proliferation, 
breakdown of their ECM and basement membrane is 
necessary, which is followed by the switch of VSMC 
from contractile to synthetic phenotype. MMPs 
degrade type IV collagen in the basement membrane 
of VSMC and many ECM and non-ECM components, 
thus allowing cell migration and ECM re-synthesize.13 
In fact, cultured VSMC transfected with small 
inhibitory MMP-2 RNA or incubated with a MMP-2 
antibody inhibited VSMC migration and their capacity 
to invade a Matrigel barrier in vitro.14, 15 MMPs may 
also contribute to VSMC migration by degrading type 
I collagen as the platelet derived growth factor-
mediated VSMC migration in the presence of type I 
collagen cleavage products and αvβ3 integrins, but not 
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in the presence of the native collagen.16 MMP-2 may 
also activate transforming growth factor-β that is 
involved in the phenotype switch of VSMC and the 
vascular rigidity.17 Furthermore, in the synthetic 
phenotype of VSMC, some cytoskeleton and 
contractile proteins are down-regulated.3, 18 
 Deoxycorticosterone acetate (DOCA) salt 
rats showed reduced calponin levels in femoral arteries 
and VSMC proliferation. This event is controlled by 
many transcriptional regulatory pathways, such as the 
serum response factor and its cofactor myocardin.18 
DOCA salt rats also showed reduced levels of 
myocardin throughout the media of femoral arteries 
and isolated VSMC.18 MMP-2 may be more abundant 
in the synthetic than contractile VSMC.19 Increased 
MMP activity is associated with reduced cytoskeleton 
proteins, which resulted in VSMC migration and 
vascular remodeling of human saphenous vein 
submitted to an injury by a surgery procedure.20 
 
Concluding remarks  
Increased MMPs activity induces ECM 
proteolysis and VSMC phenotype switch and 
migration, which contribute to the maladaptive 
vascular remodeling of hypertension. Understanding 
the mechanisms that underlie the VSMC phenotype 
switch and migration may contribute to find new 
strategies to treat hypertension and other 
cardiovascular diseases. Targeting MMPs may reduce 
VSMC migration and the arterial maladaptation caused 
by hypertension and its fatal cardiovascular events. 
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